EGFR and non-small cell lung carcinoma: To the best of our knowledge, current study is the first one showing a significantly favorable OS in patients with EGFR exon 19 deletion, when compared with other mutations in advanced NSCLC patients treated with either first- or second-generation EGFR-TKIs as first-line therapy.